Xortx Therapeutics (XRTX) announced the pricing of a public offering of 2.66M common shares at an offering price of $1.88 for gross proceeds of $5M, prior to deducting placement agent’s fees and other offering expenses. The offering is expected to close on or about May 15, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. E.F. Hutton & Co. is acting as exclusive placement agent for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Therapeutics Prices US$5 Million Public Offering to Fund Late-Stage Kidney and Gout Pipeline
- XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold
- XORTX Regains Nasdaq Listing Compliance After Reverse Stock Split
- Xortx Therapeutics meets Nasdaq continued listing requirements
- XORTX Closes US$3 Million Acquisition of Vectus Kidney Anti‑Fibrotic Program